January 22, 2014New England Journal of Medicine1,989 citationsOpen Access
View Full PaperTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Key Points
Key points are not available for this paper at this time.
Abstract
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).